

# Alpha Mannosidosis Market To Grow At Huge Rate Of 56% With The Use Of Enzyme Replacement Therapy

*The Business Research Company's Alpha Mannosidosis Market 2022 - Opportunities And Strategies – Global Forecast To 2030*


LONDON, GREATER LONDON, UK, June 14, 2022 /EINPresswire.com/ -- The use of enzyme replacement therapy is increasingly gaining traction in the [alpha mannosidosis market](#). Lamzede (velmanase alfa) is a long-term enzyme replacement therapy in adults, adolescents, and children to help treat mild to moderate forms of alpha-mannosidosis. It is a recombinant human alpha-mannosidase developed as an intravenous enzyme replacement therapy (ERT) to administer the medicine into the bloodstream in order to replace the function of the deficient enzyme in the body. The therapy aims to normalize oligosaccharide levels in the body, which ultimately prevents the progression of the disease and the formation of abnormalities.

The global [alpha mannosidosis market size](#) reached a value of nearly \$7.60 million in 2020 to \$70.06 million in 2025 at a compound annual growth rate of 55.9%. The alpha mannosidosis market share is then expected to grow at a CAGR of 15.4% from 2025 and reach \$143.14 million in 2030.

Read more on the Global Alpha Mannosidosis Market Report

<https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market>

Rising regulatory support for the drug approval of rare diseases in alpha mannosidosis is expected to drive the global alpha mannosidosis market growth in the forecast period. The inherently small population of patients with a rare disease can also make conducting clinical trials difficult. But to tackle this, in 2021, FDA announced providing support for the development and evaluation of new treatments for rare diseases making it a key priority. The FDA has



Alpha Mannosidosis Global Market 2022 - Opportunities And Strategies – Global Forecast To 2030

authority to grant orphan-drug designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including: tax credits for qualified clinical trials, exemption from user fees and potential seven years of market exclusivity after approval. Thus, rising support for regulatory bodies will propel the alpha mannosidosis market.

Major players covered in the global alpha mannosidosis industry are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex.

TBRC's alpha mannosidosis market report is segmented by therapy type into bone marrow transplant (BMT), enzyme replacement therapy (ERT), peripheral blood stem cell transplantation (PBSCT), by indication into type I, type II, type III, by end user into hospital, specialty clinics.

Alpha Mannosidosis Market 2022 - By Therapy Type (Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT)), By Indication (Type I, Type II, Type III), By End User (Hospital, Specialty Clinics), And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides a alpha mannosidosis market overview, forecast alpha mannosidosis market size and growth for the whole market, alpha mannosidosis market segments, geographies, alpha mannosidosis market trends, alpha mannosidosis market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Alpha Mannosidosis Market Report

<https://www.thebusinessresearchcompany.com/sample.aspx?id=5537&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Transplant Diagnostics Global Market Report 2022 – By Type (Reagent & Consumables, Instrument, Software & Services), By Transplant Type (Solid Organ, Stem Cell), By End User (Hospitals And Transplant Centers, Research Laboratories & Transplant Centers, Commercial Service Providers), By Technology (Non Molecular Assay, Molecular Assay), By Organ (Kidney, Liver, Heart, Lung, Pancreas) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report>

Blood Transfusion Diagnostics Global Market Report 2022 – By Type (Instruments And Kits, Reagents), By End User (Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies), By Technology (Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence Assay, Rapid Test), By Application (Blood Grouping, Disease Screening) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report>

Stem Cell Therapy Global Market Report 2022 – By Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells), By Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders), By End-User (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report>

#### About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [info@tbrc.info](mailto:info@tbrc.info)

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/576701926>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.